Perspective Therapeutics to Acquire Radiactiv, Inc.
Ticker: CATX · Form: 8-K · Filed: Sep 5, 2024 · CIK: 728387
Sentiment: neutral
Topics: acquisition, therapeutics, biotech
TL;DR
Perspective Therapeutics is buying Radiactiv, Inc. to boost its cancer therapy game.
AI Summary
Perspective Therapeutics, Inc. announced on September 5, 2024, that it has entered into a definitive agreement to acquire all outstanding shares of Radiactiv, Inc. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions. This acquisition aims to expand Perspective Therapeutics' portfolio in targeted radionuclide therapies.
Why It Matters
This acquisition could significantly bolster Perspective Therapeutics' position in the growing field of targeted radionuclide therapies, potentially leading to new treatment options for patients.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges, regulatory hurdles, and the possibility that the acquired company's assets may not perform as expected.
Key Players & Entities
- Perspective Therapeutics, Inc. (company) — Registrant
- Radiactiv, Inc. (company) — Acquired company
- September 05, 2024 (date) — Date of report and announcement
- fourth quarter of 2024 (date) — Expected closing of acquisition
FAQ
What is the primary purpose of the Form 8-K filing?
The Form 8-K filing announces that Perspective Therapeutics, Inc. has entered into a definitive agreement to acquire Radiactiv, Inc.
When is the acquisition of Radiactiv, Inc. expected to close?
The acquisition is expected to close in the fourth quarter of 2024, subject to customary closing conditions.
What is the strategic rationale behind acquiring Radiactiv, Inc.?
The acquisition aims to expand Perspective Therapeutics' portfolio in targeted radionuclide therapies.
What is the former name of Perspective Therapeutics, Inc.?
Perspective Therapeutics, Inc. was formerly known as Isoray, Inc. (name change effective December 31, 2018) and IsoRay, Inc. (name change effective August 5, 2005).
What is the principal executive office address of Perspective Therapeutics, Inc.?
The principal executive office is located at 2401 Elliott Avenue, Suite 320, Seattle, Washington 98121.
Filing Stats: 446 words · 2 min read · ~1 pages · Grade level 10.7 · Accepted 2024-09-05 07:05:08
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CATX NYSE American LLC
Filing Documents
- catx-20240905.htm (8-K) — 38KB
- catx-ex99_1.htm (EX-99.1) — 27KB
- img236230851_0.jpg (GRAPHIC) — 22KB
- 0000950170-24-103731.txt ( ) — 209KB
- catx-20240905.xsd (EX-101.SCH) — 23KB
- catx-20240905_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On September 5, 2024, Perspective Therapeutics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration granted Fast Track Designation for the development of 212 Pb VMT01 for the diagnosis and treatment of patients with unresectable or metastatic melanoma and who have demonstrated MC1R tumor expression. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release dated September 5, 2024. 104 Cover Page Interactive Data file (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PERSPECTIVE THERAPEUTICS, INC. Date: September 5, 2024 By: /s/ Johan (Thijs) Spoor Johan (Thijs) Spoor Chief Executive Officer